Deep Brain Therapy With Low-intensity Ultrasound for Treatment of Cognitive Impairment
The trial, sponsored by the University of Utah, aims to evaluate a novel non-invasive therapeutic approach for Alzheimer's disease, a condition with significant unmet medical need and a growing market. The use of low-intensity ultrasound for cognitive impairment may position the Diadem prototype as a competitive alternative to existing pharmacological treatments, particularly if it demonstrates efficacy in improving cognitive outcomes. The Alzheimer's disease market is projected to reach $20 billion by 2025, highlighting the commercial potential of successful interventions. However, the termination of this trial due to IRB administrative closure raises concerns regarding regulatory compliance and operational viability, necessitating further diligence on the sponsor's capacity to navigate these challenges.
Indication: Alzheimer Disease
Modality: medical device
Target: Low-intensity transcranial focused ultrasound stimulation targeting deep brain structures associated with cognitive impairment in Alzheimer's disease.
Sponsor: University of Utah
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 14, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Low-intensity transcranial focused ultrasound stimulation targeting deep brain structures associated with cognitive impairment in Alzheimer's disease.
View original source fields
Condition raw: Alzheimer Disease, Dementia, Cognitive Impairment
Condition normalized: Alzheimer Disease, Dementia, Cognitive Impairment
Modality raw: medical device
Modality normalized: medical device
Target raw: Low-intensity transcranial focused ultrasound stimulation targeting deep brain structures associated with cognitive impairment in Alzheimer's disease.
Target normalized: Low-intensity transcranial focused ultrasound stimulation targeting deep brain structures associated with cognitive impairment in Alzheimer's disease.